In tumor-bearing animals, the membrane phospholipid phosphatidylserine (PS) suppresses
immune responses, suggesting that PS signaling could counteract the antitumor effect of …

Checkpoint blockade therapy targeting the programmed-death ligand 1 (PD-L1) and its
receptor programmed cell death 1 promotes T-cell-mediated immunosurveillance against …

Lysophosphatidic acid (LPA) refers to a family of simple phospholipids that act as ligands for
G protein-coupled receptors. While LPA exerts effects throughout the body in normal …

Recent clinical success of immunotherapy that inhibits the negative immune regulatory
pathway programmed cell death protein‐1/PD‐1 ligand 1 (PD‐1/PD‐L1) has initiated a new …

Lysophosphatidic acid (LPA), a naturally occurring bioactive phospholipid, activates G
protein‐coupled receptors (GPCRs), leading to regulation of diverse cellular events …

To become resistant, cancer cells need to activate and maintain molecular defense
mechanisms that depend on an energy trade-off between resistance and essential functions …

We have recently reported that the PD-1 and CTLA4 signaling pathways are active in both
effector and regulatory T cells, causing profound immune dysfunctions in the tumor …

Aberrant energy status contributes to multiple metabolic diseases, including obesity,
diabetes, and cancer, but the underlying mechanism remains elusive. Here, we report that …

Advances in understanding the role and molecular mechanisms underlying immune
surveillance and control of (pre) malignancies is revolutionizing clinical practice in the …

Cholesterol, an essential molecule for cell structure, function, and viability, plays crucial
roles in the development, progression, and survival of cancer cells. Earlier studies have …